PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness

Programmed death ligand-1 (PD-L1), a promising antitumor target, has proven clinical value against many malignancies. However, the PD-L1 content of Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and its correlation with clinical outcomes remain unclear. This study aimed to investigate PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kun, Qu, Yuanyuan, Dai, Bo, Zhao, Jian-Yuan, Gan, Hualei, Shi, Guohai, Zhu, Yiping, Shen, Yijun, Zhu, Yao, Zhang, Hailiang, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437001/
https://www.ncbi.nlm.nih.gov/pubmed/28522811
http://dx.doi.org/10.1038/s41598-017-02005-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437001/
https://www.ncbi.nlm.nih.gov/pubmed/28522811
http://dx.doi.org/10.1038/s41598-017-02005-7

Ejemplares similares